Eli Lilly & Co. logo
Daniel Acker/Bloomberg
Eli Lilly posted third-quarter earnings of $1.94 a share, 2 cents below analysts’ estimates, but the stock was rising after the drug giant boosted its full-year guidance.
Eli Lilly
‘s revenue in the third quarter was $6.77 billion. Analysts expected sales of $6.64 billion.
Eli Lilly reported year-earlier earnings of $1.54 a share on revenue of $5.74 billion.
The company said Tuesday it expects full-year adjusted earnings of $7.95 to $8.05 a share, vs. prior guidance of $7.80 to $8 a share. Analysts have been expecting profit of $7.90 a share.
Eli Lilly forecast revenue for the full year of $27.2 billion to $27.6 billion. Its earlier forecast was revenue of $26.8 billion to $27.4 billion.
Eli Lilly said third-quarter Trulicity revenue was $1.6 billion, 45% higher than a year earlier and above Wall Street estimates.
Revenue from Covid-19 antibodies was $217.1 million, above forecasts of about $161 million.
The stock was rising 0.39% to $246 in premarket trading.
Write to Joe Woelfel at [email protected]
